Toggle light / dark theme

Dr yu shrike zhang phd is assistant professor at harvard medical school and associate bioengineer at brigham and women’s hospital.

Dr. Zhang’s research interests include symbiotic tissue engineering, 3D bio-printing, organ-on-a-chip technology, biomaterials, regenerative engineering, bioanalysis, nanomedicine, and biology.

His scientific contributions have been recognized by over 40 regional, national and international awards. He has been invited to deliver more than 110 lectures worldwide, and has served as reviewer for more than 500 manuscripts for as many as 50 journals.

Dr. Zhang is serving as Editor-in-Chief for Microphysiological Systems, and is Associate Editor for Bio-Design and Manufacturing, Nano Select, Aggregate, and Essays in Biochemistry.

He is also on the Editorial Board of Biofabrication, Bioprinting, Advanced Healthcare Materials, Discover Materials, BMC Biomedical Engineering, Materials Today Bio, and Chinese Chemical Letters, the Editorial Advisory Board of Heliyon and Biomicrofluidics, the International Advisory Board of Advanced NanoBiomed Research and Advanced Materials Technologies, and the Advisory Panel of Nanotechnology.

Dr. Zhang has his PhD in Biomedical Engineering from Georgia Institute of Technology / Emory, his M.S. in Bioengineering and Biomedical Engineering from Washington University in St. Louis, and his B.Eng. in Biomedical Engineering Southeast University in China.

At a time when more companies are building machine learning models, Arthur.ai wants to help by ensuring the model accuracy doesn’t begin slipping over time, thereby losing its ability to precisely measure what it was supposed to. As demand for this type of tool has increased this year, in spite of the pandemic, the startup announced a $15 million Series A today.

The investment was led by Index Ventures with help from newcomers Acrew and Plexo Capital, along with previous investors Homebrew, AME Ventures and Work-Bench. The round comes almost exactly a year after its $3.3 million seed round.

As CEO and co-founder Adam Wenchel explains, data scientists build and test machine learning models in the lab under ideal conditions, but as these models are put into production, the performance can begin to deteriorate under real-world scrutiny. Arthur.ai is designed to root out when that happens.

Mojo Vision has developed prototypes for contact lenses that enable people to see augmented reality images as overlays on the real world. And now it has teamed up with Menicon, Japan’s largest and oldest maker of contact lenses, to further develop the product.

Saratoga, California-based Mojo Vision has developed a smart contact lens with a tiny built-in display that lets you view augmented reality images on a screen sitting right on your eyeballs. It’s a pretty amazing innovation, but the company has to make sure that it works with contact lenses as they have been built for decades. The partnership with Menicon will help the company do that, Mojo Vision chief technology officer Mike Wiemer said in an interview with VentureBeat.

“It’s a development agreement, and it could turn into a commercial agreement,” Wiemer said. “I’m very excited to work with them.”

A new label-free optical imaging technique based on unscattered light can detect nanoparticles as small as 25 nm in diameter. The technology overcomes several limitations of other advanced methods for imaging tiny particles, and its developers at the University of Houston and the University of Texas M D Anderson Cancer Center in the US say it might be used to study viruses and other structures at the molecular level.

Imaging nanoscale objects via optical techniques is difficult for two reasons. First, the objects’ small size means that they scatter little light, making it hard to distinguish them from the background. Second, individual nano-objects within a close-packed group tend to be separated by distances that are smaller than the diffraction limit for visible light (around a few hundred nanometres) making it impossible to resolve them with conventional methods.

Today we are going to discuss the topic drug enforcement from a very interesting technological angle.

Brian Drake, is the Director of Artificial Intelligence for the Defense Intelligence Agency’s (DIA) Directorate of Science and Technology. Mr. Drake works with the DIA’s Future Capabilities and Innovation Office, and he also leads an initiative to test the effectiveness of different applications of artificial intelligence at solving various mission problems, including using AI to combat the opioid crisis with a DIA program known as SABLE SPEAR.

Previous to this role Brian was a Senior Intelligence Analyst and Branch Chief in the DIA’s Americas and Transregional Threats Center (ATTC) and prior to joining ATTC, Mr. Drake was a Management Analyst with DIA’s Chief of Staff.

For DIA’s intelligence analysis mission, he has worked worldwide targets in narcotics, emerging and disruptive technologies, and weapons of mass destruction.

Mr. Drake was stationed in the Pentagon as an Intelligence Briefer in the Executive Support Office, served on the Information Review Task Force, and has led several interagency technical and counterterrorism intelligence teams.

Prior to his time in DIA, Mr. Drake was a management consultant at Deloitte and Toffler Associates where he served commercial clients in various industries and government clients at the ODNI, FBI, CIA, NSA, and the US State Department.

The French armed forces now have permission to develop “augmented soldiers” following a report from a military ethics committee.

The report, released to the public on Tuesday, considers medical treatments, prosthetics and implants that improve “physical, cognitive, perceptive and psychological capacities,” and could allow for location tracking or connectivity with weapons systems and other soldiers.